[go: up one dir, main page]

FI965224A7 - Polynukleotidirokote papilloomavirukselle - Google Patents

Polynukleotidirokote papilloomavirukselle Download PDF

Info

Publication number
FI965224A7
FI965224A7 FI965224A FI965224A FI965224A7 FI 965224 A7 FI965224 A7 FI 965224A7 FI 965224 A FI965224 A FI 965224A FI 965224 A FI965224 A FI 965224A FI 965224 A7 FI965224 A7 FI 965224A7
Authority
FI
Finland
Prior art keywords
papillomavirus
polynucleotide vaccine
vaccine
polynucleotide
Prior art date
Application number
FI965224A
Other languages
English (en)
Swedish (sv)
Other versions
FI965224L (fi
FI965224A0 (fi
Inventor
John J Donnelly
Margaret A Liu
Douglas Martinez
Donna Mont-Gomery
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI965224L publication Critical patent/FI965224L/fi
Publication of FI965224A0 publication Critical patent/FI965224A0/fi
Publication of FI965224A7 publication Critical patent/FI965224A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
FI965224A 1994-06-30 1995-06-01 Polynukleotidirokote papilloomavirukselle FI965224A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26842494A 1994-06-30 1994-06-30
PCT/US1995/006915 WO1996000583A1 (en) 1994-06-30 1995-06-01 Polynucleotide vaccine for papillomavirus

Publications (3)

Publication Number Publication Date
FI965224L FI965224L (fi) 1996-12-27
FI965224A0 FI965224A0 (fi) 1996-12-27
FI965224A7 true FI965224A7 (fi) 1996-12-27

Family

ID=23022939

Family Applications (1)

Application Number Title Priority Date Filing Date
FI965224A FI965224A7 (fi) 1994-06-30 1995-06-01 Polynukleotidirokote papilloomavirukselle

Country Status (20)

Country Link
US (1) US5866553A (fi)
EP (1) EP0768893B1 (fi)
JP (1) JPH10501987A (fi)
CN (1) CN1156966A (fi)
AT (1) ATE233101T1 (fi)
AU (1) AU701973B2 (fi)
CA (1) CA2193365C (fi)
CZ (1) CZ375296A3 (fi)
DE (1) DE69529748T2 (fi)
ES (1) ES2191052T3 (fi)
FI (1) FI965224A7 (fi)
HU (1) HU220747B1 (fi)
IL (1) IL113817A (fi)
MX (1) MX9700229A (fi)
NO (1) NO965590L (fi)
NZ (1) NZ288045A (fi)
PL (1) PL180639B1 (fi)
SK (1) SK164196A3 (fi)
WO (1) WO1996000583A1 (fi)
ZA (1) ZA954641B (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
AU722326B2 (en) * 1997-02-14 2000-07-27 Merck & Co., Inc. Polynucleotide vaccine formulations
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
WO1999052463A1 (en) * 1998-04-14 1999-10-21 Merck & Co., Inc. Needleless administration of polynucleotide formulations
EP1108035B1 (en) * 1998-09-04 2007-08-08 Sanofi Pasteur Limited Treatment of cervical cancer
CA2361421A1 (en) * 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
CA2365416C (en) * 1999-03-26 2011-06-14 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
ES2372592T3 (es) * 1999-04-08 2012-01-24 Intercell Usa, Inc. Formulación seca para la inmunización transcutánea.
EP1212358B1 (en) * 1999-08-25 2004-12-15 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells
US7001995B1 (en) 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
SE0002498D0 (sv) * 2000-07-03 2000-07-03 Stefan Schwartz Papillomavirus vaccine
KR20020005332A (ko) * 2000-07-10 2002-01-17 정상훈 탈모증 치료용 키트
PT1372708E (pt) * 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
CZ304169B6 (cs) * 2001-06-22 2013-12-04 The Wistar Institute Of Anatomy And Biology Replikacne defektní opicí adenovirový vektor, zpusob jeho prípravy a lécivo, imunogenní kompozice a vakcína obsahující rekombinantní adenovirus
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
CA2509973C (en) 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
KR20070002014A (ko) * 2004-02-13 2007-01-04 노드 파마수티칼스, 인코포레이티드 치료용 인산칼슘 입자, 그 제조 방법 및 그 이용 방법
EP1811941A4 (en) * 2004-11-01 2008-09-10 Biosante Pharmaceuticals Inc CALCIUM PHOSPHATE THERAPEUTIC PARTICLES FOR AESTHETIC OR COSMETIC MEDICINE, AND METHODS OF MAKING AND USING THE SAME
CA2596698C (en) * 2005-02-01 2017-05-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies
BRPI0815818A2 (pt) 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 truncada do papiloma vírus humano tipo 18
CN101293918B (zh) * 2007-04-29 2013-03-27 北京万泰生物药业股份有限公司 截短的人乳头瘤病毒16型l1蛋白
US8748127B2 (en) * 2007-05-29 2014-06-10 Xiamen University Truncated L1 protein of human papillomavirus type 6
JP2016514672A (ja) * 2013-03-15 2016-05-23 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗原およびアジュバントとしてのインターロイキン−２３を有するワクチン

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
WO1986005816A1 (en) * 1985-04-04 1986-10-09 Georgetown University Type-specific papillomavirus dna sequences and peptides
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
CA2049287C (en) * 1989-03-21 2005-03-29 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
DE122007000019I1 (de) * 1991-07-19 2007-07-26 Univ Queensland Impfstoffen gegen Papillomavirus
US5376542A (en) * 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
ZA935355B (en) * 1992-08-07 1995-01-23 American Home Prod Recombinant andenovirus vaccines
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization

Also Published As

Publication number Publication date
CA2193365C (en) 2007-04-03
ZA954641B (en) 1996-01-26
IL113817A (en) 2001-03-19
DE69529748T2 (de) 2003-10-16
JPH10501987A (ja) 1998-02-24
NZ288045A (en) 1998-08-26
DE69529748D1 (de) 2003-04-03
AU701973B2 (en) 1999-02-11
SK164196A3 (en) 1997-08-06
NO965590L (no) 1997-02-28
IL113817A0 (en) 1995-08-31
FI965224L (fi) 1996-12-27
WO1996000583A1 (en) 1996-01-11
FI965224A0 (fi) 1996-12-27
PL317874A1 (en) 1997-04-28
ES2191052T3 (es) 2003-09-01
HU220747B1 (hu) 2002-05-28
MX9700229A (es) 1997-04-30
US5866553A (en) 1999-02-02
HUT76446A (en) 1997-09-29
HU9603562D0 (en) 1997-02-28
NO965590D0 (no) 1996-12-27
PL180639B1 (pl) 2001-03-30
CA2193365A1 (en) 1996-01-11
CZ375296A3 (en) 1997-08-13
CN1156966A (zh) 1997-08-13
EP0768893B1 (en) 2003-02-26
EP0768893A1 (en) 1997-04-23
ATE233101T1 (de) 2003-03-15
AU2694595A (en) 1996-01-25

Similar Documents

Publication Publication Date Title
FI965224L (fi) Polynukleotidirokote papilloomavirukselle
FI964592L (fi) Papilloomavirusrokotteita
FI972034L (fi) Polynukleotidi tuberkuloosirokote
BR9711853A (pt) Vacinas
KR970704468A (ko) 폴리에피토프 백신(polyepitope vaccines)
NO20003302L (no) Vaksine
DE59510957D1 (de) Offsetdruckmaschine
ATE209045T1 (de) Hepatitis b impfstoff
FI971176A7 (fi) DNA-fotopilkkominen käyttäen teksapyriinejä
FI952987L (fi) Vaahdonestoaine
DE69528497D1 (de) Lüfter-Trockner-Einheit
GB9420146D0 (en) Papillomavirus vaccine
EP0967993A4 (en) ANTI-COCAINE VACCINE
FI952629L (fi) Kefiksiimivalmiste
ITMI950676A0 (it) Vaccini polinucleotidici
DK60694A (da) Liftophængt redskab
GB9417880D0 (en) Vaccine
KR970703417A (ko) 유두종 바이러스 백신(Papillomavirus vaccines)
KR960009867U (ko) 분리식 제기
GB9419969D0 (en) Vaccine
KR960022879U (ko) 벽돌
ITCO940007V0 (it) Tombola mina
ITCE940001U1 (it) Antisasso
GB9423928D0 (en) Vaccine
GB9412470D0 (en) Vaccine